Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study - Banerjee, A; Lane, D A; Torp-Pedersen, C (Thromb Haemost, 2012)
et al.